Skip to content

Single-cell Study of Osteoclast Heterogeneity and Its Mechanisms

Single-Cell RNA Sequencing Reveals the Heterogeneity and Underlying Mechanisms of Multinucleated Osteoclasts

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128402
Enrollment
Unknown
Registered
2026-07-20
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis-related fractures, including femoral neck fracture and osteoporotic vertebral compression fracture

Interventions

Osteoporotic vertebral compression fracture group:None

Sponsors

The Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients meeting either of the following conditions: (1) Patients clinically and radiologically diagnosed with femoral neck fracture and scheduled to undergo hemiarthroplasty or total hip arthroplasty; (2) Patients clinically and radiologically diagnosed with osteoporotic vertebral compression fracture and scheduled to undergo spinal surgery; 2.Surgically discarded femoral head, femoral neck bone tissue, vertebral cancellous bone, or bone marrow-like tissue that is no longer required for clinical diagnosis or treatment can be obtained during surgery; 3.Written informed consent is obtained from the patient or his/her legal representative.

Exclusion criteria

Exclusion criteria: 1.Pathological fractures (e.g., bone metastasis, multiple myeloma); 2.History of malignant tumors or primary bone tumors; 3.Severe hematological diseases (e.g., leukemia, multiple myeloma); 4.Active infections, including osteoarticular or spinal infections; 5.Severe autoimmune diseases (e.g., rheumatoid arthritis, ankylosing spondylitis); 6.Severe hepatic or renal dysfunction; 7.Long-term use (within 6 months) of glucocorticoids, immunosuppressants, or drugs significantly affecting bone metabolism; 8.Uncontrolled endocrine disorders (e.g., thyroid/parathyroid diseases); 9.Other conditions deemed inappropriate for inclusion by the investigator, including insufficient sample quality for single-cell RNA sequencing.

Design outcomes

Primary

MeasureTime frame
Composition and heterogeneity analysis of multinucleated osteoclasts and related cell populations;

Secondary

MeasureTime frame
Experimental validation of key cell populations and marker genes identified by single-cell RNA sequencing;Regulatory pathways associated with multinucleated osteoclast formation and function;

Countries

China

Contacts

Public ContactDejun Zhong

The Affiliated Hospital of Southwest Medical University

zdj_1974@163.com+86 830 3165441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026